Bladder Cancer - Results from #260

REVIEW UroToday

Efficacy of FGFR Inhibitor Derazantinib in Metastatic Urothelial Carcinoma - Expert Commentary July 8, 2024

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations July 8, 2024

Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion. July 8, 2024

Contemporary survival in metastatic bladder cancer patients: A population-based study. July 8, 2024

Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding. July 8, 2024

Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. July 5, 2024

N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review. July 5, 2024

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. July 4, 2024

Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy. July 4, 2024

Efficacy of Neoadjuvant Chemotherapy in Patients with MIBC Undergoing Radiation - Expert Commentary July 3, 2024

Real-world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial. July 3, 2024

CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer. July 3, 2024

Prognostic Factors of Relapse in Surgically Resected Small Cell Neuroendocrine Carcinomas of the Urothelial Tract (SCNEC-URO) July 2, 2024

Integrative Clinical and Genomic Characterization of MTAP-Deficient Metastatic Urothelial Cancer July 2, 2024

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. July 2, 2024

Association Between Residual Urine Volume and Recurrence Among Patients at High Risk of Non-Muscle-Invasive Bladder Carcinoma With Versus Without Bacillus Calmette-Guérin Treatment. July 2, 2024

Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience. July 1, 2024

The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder. July 1, 2024

Transcriptome Analysis in Patients With Muscle-invasive Bladder Cancer. July 1, 2024

Mismatch Repair Deficiency and Microsatellite Instability in Urothelial Carcinoma: A Systematic Review and Meta-Analysis June 28, 2024

Page 14 of 517